Recent News Releases

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination MELBOURNE,...

Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena. Monteriggioni (SI), July 19, 2019 Seqirus, a global...

This news release is intended for business and trade media only. Summit, New Jersey 15 Jul 2019 Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming...

Melbourne, Australia - 1 July 2019 - Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor...

- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address...

Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug...

Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future Zurich and Basel, 26 May 2019 Nanopharmaceutics promises...

ZURICH, 21 May 2019 – Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to...

16 May 2019 Marburg, Germany - 16 May 2019 - Global biotherapeutics leader CSL Behring today announced that the company has named five recipients of the 2019 Professor Heimburger Award for...

15 May 2019 KING OF PRUSSIA, PA – May 15, 2019 - CSL today named Dr. Paul McKenzie, an accomplished global leader with diverse biotechnology experience, as Chief Operating Officer (COO),...

Veltassa® (patiromer) enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. ZURICH, 10 May...

Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members...

25 Apr 2019 KING OF PRUSSIA, Pa. – 25 April 2019 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial...

Agreement to jointly commercialise the new diabetic kidney disease (DKD) indication for INVOKANA® (canagliflozin) in the US Only diabetes treatment indicated to slow down the progression of DKD...

Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...

26 Mar 2019 Hizentra® [human normal immunoglobulin, 20%, subcutaneous] is the first and only subcutaneous immunoglobulin approved for the maintenance treatment of CIDP in Japan, based on findings...

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...

VIFOR PHARMA GROUP REPORTS STRONG 2018 RESULTS, EXCEEDING RAISED GUIDANCE THE VIFOR PHARMA GROUP REPORTED A STRONG SALES AND PROFIT PERFORMANCE IN 2018 WITH CONTINUED SOLID GROWTH FROM ITS THREE...

04 Feb 2019 MONTREAL and KING OF PRUSSIA, Pa. – 4 February 2019 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has...

Companies plan to file for full marketing approval to EMA and FDA in 2020 MOUNTAIN VIEW, Calif. and ZURICH, 24 January, 2019 – ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma...

Re-analysis of the PIVOTAL data by the investigators has revealed that proactive, high-dose Venofer® compared to reactive, low-dose Venofer® resulted in: Superiority and statistically...

16 Jan 2019 KING OF PRUSSIA, Pa. – January 16, 2019 – Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL,...

This news release is intended for Health Professional media only. Seqirus to launch its cell-based influenza vaccine in Europe for the 2019-20 season Real-world data indicates cell-based influenza...

07 Jan 2019 King of Prussia, Pa – Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, today announced that...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...